- GSK announced the start of pCPA negotiations for Blenrep (belantamab mafodotin for injection) in combination with bortezomib and dexamethasone, or with pomalidomide and dexamethasone, for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
- The negotiations represent an important step toward expanding access to new treatment options for Canadians living with multiple myeloma, an incurable blood cancer with significant treatment burden and ongoing unmet need.
- GSK said its focus will be on supporting a process that balances timely patient access with long-term healthcare sustainability, while working alongside the pCPA, provincial health systems, clinicians, and the broader myeloma community.
- Myeloma Canada welcomed the development, highlighting the potential for therapies like Blenrep to not only extend survival but also help reduce treatment burden and improve quality of life for patients, including the possibility of receiving care closer to home.
Takeaways
Blenrep’s pCPA negotiations are an important step toward broader Canadian access to a new multiple myeloma option, especially because the drug is being positioned in combination regimens that could reduce treatment burden and potentially move care closer to home. For GSK, the big market issue is balancing faster reimbursement with province-level affordability, since myeloma is a chronic, high-cost cancer area with ongoing demand for newer therapies.
The bigger implication is that Blenrep could help GSK re-enter a competitive myeloma market and give provinces another pathway for patients who have already gone through prior therapy, but uptake will likely depend on how well pricing, clinical value, and real-world logistics align with public funding priorities.
Source: CA Newswire
